STOCK TITAN
  1. Home
  2. Financials
  3. RGNT

Regentis Biomaterials Ltd Financials

RGNT
Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE December

This page shows Regentis Biomaterials Ltd (RGNT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score pending refresh

We are recalculating Regentis Biomaterials Ltd's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Earnings Quality Low Quality
0.10x

For every $1 of reported earnings, Regentis Biomaterials Ltd generates $0.10 in operating cash flow (-$1.4M OCF vs -$13.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk
-88.2x

Regentis Biomaterials Ltd earns $-88.2 in operating income for every $1 of interest expense (-$7.0M vs $79K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
N/A
Net Income
-$13.6M

Regentis Biomaterials Ltd reported -$13.6M in net income in fiscal year 2025.

EPS (Diluted)
$-24.16

Regentis Biomaterials Ltd earned $-24.16 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$7.4M

Regentis Biomaterials Ltd held $7.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
5M

Regentis Biomaterials Ltd had 5M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
-287.7%

Regentis Biomaterials Ltd's ROE was -287.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
N/A

RGNT Income Statement

Metric Q4'25 Q4'24
Revenue N/A N/A
Cost of Revenue N/A N/A
Gross Profit N/A N/A
R&D Expenses N/A N/A
SG&A Expenses N/A N/A
Operating Income N/A N/A
Interest Expense N/A N/A
Income Tax N/A N/A
Net Income N/A N/A
EPS (Diluted) N/A N/A

RGNT Balance Sheet

Metric Q4'25 Q4'24
Total Assets $7.6M+1480.5% $482K
Current Assets N/A N/A
Cash & Equivalents $7.4M N/A
Inventory N/A N/A
Accounts Receivable N/A N/A
Goodwill N/A N/A
Total Liabilities $2.9M-93.1% $41.6M
Current Liabilities $2.9M-55.7% $6.5M
Long-Term Debt N/A N/A
Total Equity $4.7M+111.5% -$41.1M
Retained Earnings -$55.8M-32.4% -$42.1M

RGNT Cash Flow Statement

Metric Q4'25 Q4'24
Operating Cash Flow N/A N/A
Capital Expenditures N/A N/A
Free Cash Flow N/A N/A
Investing Cash Flow N/A N/A
Financing Cash Flow N/A N/A
Dividends Paid N/A N/A
Share Buybacks N/A N/A

RGNT Financial Ratios

Metric Q4'25 Q4'24
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Margin N/A N/A
Return on Equity N/A N/A
Return on Assets N/A N/A
Current Ratio N/A N/A
Debt-to-Equity 0.61 N/A
FCF Margin N/A N/A

Frequently Asked Questions

No, Regentis Biomaterials Ltd (RGNT) reported a net income of -$13.6M in fiscal year 2025.

Regentis Biomaterials Ltd (RGNT) reported diluted earnings per share of $-24.16 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Regentis Biomaterials Ltd (RGNT) has a return on equity of -287.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Regentis Biomaterials Ltd (RGNT) generated -$1.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Regentis Biomaterials Ltd (RGNT) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Regentis Biomaterials Ltd (RGNT) had 5M shares outstanding as of fiscal year 2025.

Regentis Biomaterials Ltd (RGNT) had a debt-to-equity ratio of 0.61 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Regentis Biomaterials Ltd (RGNT) had a return on assets of -179.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Regentis Biomaterials Ltd (RGNT) had $7.4M in cash against an annual operating cash burn of $1.4M. This gives an estimated cash runway of approximately 64 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Regentis Biomaterials Ltd (RGNT) has an earnings quality ratio of 0.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Regentis Biomaterials Ltd (RGNT) has an interest coverage ratio of -88.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top